Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 5Withdrawn 4Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 32Thoracic 19Breast 19Head & Neck 11CNS 11Genitourinary 9Sarcoma 6Gynecologic 6Other solid neoplasm 5Other neoplasm 4Tumor-Agnostic 2Plasma cell 2Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Other 1Endocrine 1

Conditions

Melanoma 1Carcinoma, Basal Cell 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Celecoxib × Dermatologic × Clear all
NCT00023621 2013-06-26

Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00197912 2010-04-26

Dendritic Cell Based Therapy of Malignant Melanoma

Herlev Hospital

Phase 1/2 Completed
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡